SEC Comment Letter for Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251) (CTXR) — May 31, 2017
Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251)
Date: May 31, 2017 · CIK: 0001506251 · Accession: 0000000000-17-018992
AI Filing Summary & Sentiment
Reasoning
Letter
May 31, 2017 Myron Holubiak President and Chief Executive Officer Citius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, New Jersey 07016 Citius Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed May 12, 2017 File No. 333-217956Re: Dear Mr. Holubiak: We have limited our review of your registration statement to those issues we have addressed in our comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to our comment, we may have additional comments. Form S-1 filed May 12, 2017 Cover Page We note that your common stock is currently listed on the OTCQB Venture Market and that you intend to apply to have your common stock listed on the Nasdaq Capital Market. Where you disclose on the cover page the recent share price of your common stock as quoted on the OTCQB, please expand to state that the share price on the OTCQB may not be indicative of the market price on the Nasdaq Capital Market.1. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Myron Holubiak Citius Pharmaceuticals, Inc. 2 PageMay 31, 2017 Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. You may contact Johnny Gharib at (202) 551-3170 or Mary Beth Breslin at (202) 551- 3625 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Erica B. Jackson, Esq.
Show Raw Text
May 31, 2017
Myron Holubiak
President and Chief Executive Officer
Citius Pharmaceuticals, Inc.
11 Commerce Drive, First Floor
Cranford, New Jersey 07016
Citius Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed May 12, 2017
File No. 333-217956Re:
Dear Mr. Holubiak:
We have limited our review of your registration statement to those issues we have
addressed in our comment. In our comment, we may ask you to provide us with information so
we may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to our comment, we may have additional comments.
Form S-1 filed May 12, 2017
Cover Page
We note that your common stock is currently listed on the OTCQB Venture Market and
that you intend to apply to have your common stock listed on the Nasdaq Capital
Market. Where you disclose on the cover page the recent share price of your common
stock as quoted on the OTCQB, please expand to state that the share price on the OTCQB
may not be indicative of the market price on the Nasdaq Capital Market.1.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Myron Holubiak
Citius Pharmaceuticals, Inc.
2 PageMay 31, 2017
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
You may contact Johnny Gharib at (202) 551-3170 or Mary Beth Breslin at (202) 551-
3625 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Erica B. Jackson, Esq.